Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007273 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
A Phase 2 study of Cutaneous Sarcoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 3
- Study locations
NCT07007273: Recruiting Phase 2 study of Cutaneous Sarcoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT07007273 is a Phase 2 study of Cutaneous Sarcoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07007273, a Phase 2 study of Cutaneous Sarcoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute IV infusion every 21 days (3 weeks).
Primary Outcome
Objective response rate will be determined by RECIST 1.1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
Florida
- Moffitt Cancer Center - Tampa
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2030-07 |
| Phase | Phase 2 |
What NCT07007273 shows while recruiting
NCT07007273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Cutaneous Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT07007273 reports a single indexed study location in Florida, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT07007273 about?
NCT07007273 is a clinical study titled "Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma". This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximate...
What is the current status of trial NCT07007273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2025-06-20. Estimated completion is 2030-07.
What conditions does trial NCT07007273 study?
This clinical trial studies the following conditions: Cutaneous Sarcoma.
What interventions are being tested in trial NCT07007273?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT07007273?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007273 being conducted?
This trial has 3 study locations across Florida, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07007273's enrollment target sits among peer trials
17 1904th of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI